BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Nektar Therapeutics:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-07-09 4:39 pm Purchase |
2025-07-01 | 13G | Nektar Therapeutics NKTR |
BIOTECHNOLOGY VALUE FUND L P | 1,276,595 7.400% |
1,276,595 (New Position) |
Filing |